Is complete spermiogenesis failure a good indication for spermatid conception?

Amer, Medhat; Soliman, Ehab; El-Sadek, Moustafa; Mendoza, Carmen

doi:10.1016/s0140-6736(05)61819-3

Cited by 72 publications

(40 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our experience, and as previously mentioned by others, round spermatid can be detected in some patients in whom late spermatid or spermatozoa fail to be found [14,15]. In the absence of mature spermatid or sperm, T-ROSI may be an appropriate alternative.…”

Section: Discussionsupporting

confidence: 82%

The First Successful Pregnancy Following Injection of Testicular Round Spermatid in Iran

Saremi¹,

Esfandiari²,

Salehi³

et al. 2002

Archives of Andrology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 82%

The First Successful Pregnancy Following Injection of Testicular Round Spermatid in Iran

Saremi¹,

Esfandiari²,

Salehi³

et al. 2002

Archives of Andrology

View full text Add to dashboard Cite

“…Maturation arrest at the round spermatid stage can be produced experimentally by deficiency of hormones and other regulatory factors, as well as by targeted mutation of genes for receptors, elements of signal transduction pathways or intracellular repair systems (Table I). The idea that similar molecular defects can occur spontaneously in humans (Tesarik et al, 1998b) and lead to a similar pathological picture, referred to as complete spermiogenesis failure (Amer et al, 1997), is supported by the recent detection of spontaneous mutations of the CREM gene (Table I) in some men with maturation arrest at the round spermatid stage (Weinbauer et al, 1998).…”

Section: Spermatid Conceptionmentioning

confidence: 97%

“…Therefore, we think it is time to seriously reconsider whether round spermatid nuclear injection (ROSNI) and round spermatid injection (ROSI) are solutions to non-obstructive azoospermia when no spermatozoa or mature spermatids can be identified in the TESE specimens (Silber and Johnson, 1998 (Tesarik et al, 1995Vanderzwalmen et al, 1997;Barak et al, 1998). On the other hand, with the current state of the art, the risk of ROSI failure remains high (Amer et al, 1997;Vanderzwalmen et al, 1997). The Silber et al article commenting on our opinion article on current problems with spermatid conception (Sousa et al, 1998), is actually a mere repetition of arguments that have been refuted in another recent paper (Tesarik et al, 1998a).…”

Section: Spermatid Conceptionmentioning

confidence: 99%

“…Because cells at early stages of apoptosis cannot be distinguished from healthy cells at the time of ROSI, neither can they be recognized by conventional viability tests, the risk of injecting oocytes with round spermatids carrying irreparable DNA damage is high in these cases. This can explain the low implantation rates after the transfer of embryos resulting from ROSI in cases of complete spermiogenesis failure (Amer et al, 1997;Vanderzwalmen et al, 1997). The development of methods enabling the selection of non-apoptotic spermatids for assisted reproduction is thus a major challenge for the future use of spermatid conception.…”

Section: Spermatid Conceptionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of agonist dose on in-vitro fertilization

Lashen¹,

Ledger²

1998

Human Reproduction

View full text Add to dashboard Cite

Effects of agonist dose on in-vitro fertilizationDear Sir, Alvarez et al. (1997) have made a useful contribution to this field of research. However, there are possible alternative interpretations for their findings which we feel might be usefully considered. Their study appears flawed in that there are no data concerning concentrations of follicle stimulating hormone (FSH) on day 3 of the cycle, or on previous pregnancies and their outcomes -both features are important when assessing outcome variables. In our experience, we also find that obese patients require significantly longer duration to achieve down-regulation, using the same criteria as the authors, but this has no impact on pregnancy rate.Finally, and most importantly, the chosen cut-off point of 13 days duration of gonadotrophin-releasing hormone (GnRHa) administration was not justified in their manuscript. We find this biased, since in their small sample shifting two patients from GII (longer duration) to GI (shorter duration) by choosing a cut-off of 14 or 15 days can lead to no significance in the pregnancy rate between the two groups. To demonstrate this statistically we carried out the following exercise: the reported pregnancy rates in the study for GI and GII were 44 and 20% respectively which is 9/27 and 12/45. Using the c 2 test gives P ϭ 0.027. By increasing the cut-off point by 1 or 2 days the pregnancy rates may be: 12/43 and 9/29 (assuming no change in the number of the pregnant patients) which makes P ϭ 0.06, (not significant). Furthermore, the authors did not indicate how often they measured the patients serum oestradiol to verify the concentrations Ͻ50 pg/ml. This has to be on a daily basis so that the cut-off point may be in days. However, every other day or weekly measurement of oestradiol does not give accurate duration in days. On the other hand, as the authors indicated in their study, the patients were seen in the first few days of their period for ultrasound scan and oestradiol measurement. Since their measurements were not on a specific day, inadvertent over-estimation of the days of GnRHa administration could not be ruled out. In conclusion, we feel that a prospective study is necessary to address these issues effectively. Care must be taken in over-interpreting data collected from small numbers.Reference Alvarez, C., Cremades, N., Blasco, N. and Bernabeau, R. (1997) (Alvarez et al., 1998). In response to this comment we would like to clarity that patients were separated into two groups according to the number of days of agonist administration, and the value of the median (13 days) was chosen as a cut-off point. When we chose other cut-off points (12 or 14 days), the pregnancy rate per cycle and per transfer was significantly lower in the patients group suppressed for a longer period (Neyro et al., 1994) (Tables I and II).Ovarian quiescence was verified for the first or second day of cycle with no follicular growth observed by transvaginal ultrasound and an oestradiol serum concentration of Ͻ50 pg/ml on the same day. Cer...

show abstract

“…Round or elongated spermatids were collected from patients with non-obstructive azoospermia who did not have mature spermatozoa in their testes, and some of their partners became pregnant and delivered babies. Table 1 summarizes the major reports on round spermatid injection [39][40][41][42][43][44][45][46][47][48]. As can be seen in the table, the rates of fertilization and delivery had been low, but the cause of these poor results had not yet been clearly identified.…”

Section: Spermatid Injectionmentioning

confidence: 99%

Limits to the clinical Application of ICSI.

et al. 2000

View full text Add to dashboard Cite

Microinsemination is a revolutionary and promising technique for the treatment of severe male infertility, such as severe oligozoospermia, asthenozoospermia, and the case of unexplained unfertilization in which the conventional IVF is ineffective even if semen parameters are normal. Several different microinsemination techniques, such as zona opening [1][2][3], subzona sperm injection [4, 5], and intracytoplasmic sperm injection (ICSI) [6], have been introduced. ICSI is considered the most effective technique, because ICSI has the highest fertilization rate and can be performed with the smallest number of spermatozoa. In addition, this technique is effective for functional disorders, such as disorders of capacitation, acrosome reaction, and spermegg fusion. ICSI was first reported in 1992 [6], and for the above reasons became a powerful fertilization tool in only three or four years [7, 8].At first, ICSI was indicated for the treatment of severe infertility in which the probability of pregnancy was nonexistent or very law. Its indications were then expanded to include azoospermia, and it has been fairly effective [9][10][11], but in such cases chromosomal and genetic abnormalities may be passed on to children [12][13][14]. In addition, it has been clarified that ICSI is not effective in some cases, such as necrozoospermia [15], in which there are no viable spermatozoa; immotile spermatozoa [16], in which viable spermatozoa cannot always be picked up; cases in which spermatozoa have the disorder of oocyte activation factor; and azoospermia, in which mature spermatozoa cannot be found in the testes. The present paper concerns issues that must be considered in the performance of ICSI, as well as limitations to the effectiveness of ICSI. -ReviewNecrozoospermiaIn necrozoospermia, every spermatozoa on in semen is found to be dead when analyzed by vital staining (eosin stain [17], FertiLight stain (Molecular Probes, Eugene, OR) [18]). Sperm-injected oocytes are less likely to develop when injected with dead spermatozoa than with motile spermatozoa. The rate of fertilization for ICSI ranges from 0 to 11% [15]. Since 1992, 659 patients have been treated for infertility, a total of 1,317 treatment cycles at our hospital, and there had been six treatment cycles for necrozoospermia (3 patients). Among these cases, the rate of fertilization was 33.3% (5/15 oocytes), but there were no pregnancies. Since the fertilization rate was very low, dead (nonviable) spermatozoa may reduce the oocyte activating factor or have fragmented nuclear DNA or have chromosome disintegration [19]. Even when the sperm factor is injured and nuclear DNA is damaged, fertilization is possible with ICSI, but we cannot get well developed embryos from these spermatozoa, so that there is no hope of pregnancy. In humans, the development of fertilized oocytes to 4-cell stage embryos is controlled by the maternal genes rather than the paternal ones [20], so that fertilized oocytes can develop to this stage regardless of the state of the paternal DNA. The res...

show abstract

Is complete spermiogenesis failure a good indication for spermatid conception?

Cited by 72 publications

References 3 publications

The First Successful Pregnancy Following Injection of Testicular Round Spermatid in Iran

The First Successful Pregnancy Following Injection of Testicular Round Spermatid in Iran

Effects of agonist dose on in-vitro fertilization

Limits to the clinical Application of ICSI.

Contact Info

Product

Resources

About